Mark Cuban, founder of the Mark Cuban Cost Plus Drug Company, said that genuine healthcare price relief necessitates dismantling vertically integrated insurers and controlling pharmacy benefit manager (PBM) fees, facility fees, and 340B margin abuses – a issue gaining attention in New York.
“Who exactly is going to cut their prices ? Independent physicians can barely pay their bills,” said Cuban. “Hospitals are going to get rid of facility fees or walk away from keeping 340b margins and passing that to the patient ? No. Big PBMs are going to stop charging fees ? No. Break up the big insurance companies first.”
According to the Federal Trade Commission’s (FTC) interim staff report on prescription-drug middlemen, the PBM industry is highly concentrated and increasingly linked to major insurers and affiliated pharmacies. The report indicated that these connections enable PBMs to engage in practices that “profit at the expense of patients and independent pharmacists,” including steering patients and charging opaque fees. This highlights growing policy scrutiny of PBMs’ market power.
State lawmakers are also challenging hospital “facility fees,” which can inflate bills when outpatient sites are billed as part of a hospital. By September 2025, 20 states had enacted laws to limit or make these fees more transparent, reflecting concerns that hospital consolidation allows extra charges not tied to actual patient care. Advocates argue this trend ensures savings are passed on to patients.
In New York, 340B hospitals have 6,173 contract-pharmacy arrangements, and the same 340B profile notes contract-pharmacy use has grown 8,000%+ since 2010—a scale critics say makes it easier for middlemen and hospitals to profit without patient savings.
Cuban is an American businessman, investor, and television personality known for founding the Mark Cuban Cost Plus Drug Company in 2022 to enhance transparency and affordability in prescription drug pricing. The company sells generic medications at cost plus a 15% margin and pharmacy fee, aiming to bypass traditional PBMs and reduce patient expenses.
